Drug Patent Watch

OCTOBER 2, 2023

The FDA conducted a study to identify factors that may predict the likelihood of generic drug marketing applications.

Marketing 111

Marketing Drugs FDA 111

Drug Patent Watch

JULY 25, 2024

The generic drug market has been significantly impacted by the COVID-19 pandemic, with both challenges and opportunities arising from the crisis. As the world continues to recover…

Marketing 98

Marketing Drugs 98

BioPharma Drive: Drug Pricing

SEPTEMBER 26, 2024

The withdrawal comes as trial results indicate safety concerns with the drug, Oxbryta, which was first approved in the U.S.

Trials 114

Trials Marketing Drugs 114

BioPharma Drive: Drug Pricing

AUGUST 8, 2023

The Indianapolis drugmaker is now worth more than $500 billion, higher than any other pharmaceutical company, as analysts project lucrative markets for its obesity and Alzheimer's drugs.

Marketing 98

Marketing Pharmaceutical Companies Drugs Pharmaceuticals 98

ProRelix Research

NOVEMBER 2, 2023

Although clinical trials provide useful information regarding the efficacy and safety of new drugs, biological products, and medical devices, the information captured through them is not all-encompassing. Limited patient populations, […] The post Post-Marketing Surveillance Strategies appeared first on ProRelix Research.

Marketing 98

Marketing Clinical Trials Trials Production 98

Collaborative Drug

APRIL 19, 2024

Tokyo, Japan, April 17, 2024 — In a significant move to bolster CDD Vault’s presence in the Japanese market, Collaborative Drug Discovery (CDD) is excited to announce the appointment of Mr. Yasushi Hamagashira as the new Head of Sales and Marketing for Japan.

Marketing 110

Marketing Drugs 110

Drugs.com

FEBRUARY 21, 2024

1, and the business move has left families scrambling to find a replacement for their kids.Flovent was one of the most commonly prescribed drugs for childhood asthma, but. WEDNESDAY, Feb. 21, 2024 -- A popular asthma inhaler was discontinued on Jan.

Marketing 117

Marketing Drugs 117

Fierce BioTech

OCTOBER 21, 2024

Chiefly, Sailer highlights the transformative impact of AI and machine learning in drug development, a trend which, he believes, can potentially double approval rates while reducing costs and time-to-market.

Marketing 98

Marketing Clinical Development Drug Development Drugs 98

Drug Patent Watch

AUGUST 8, 2023

A recent study explores the landscape of authorized generics in the United States pharmaceutical market. Authorized generics are brand-name drugs that are marketed without their original branding.

Marketing 96

Marketing Pharmaceuticals Drugs 96

Drugs.com

JULY 19, 2024

Food and Drug Administration on Thursday authorized the sale of the country's best-selling e-cigarette.The agency's decision only applies to several tobacco-flavored versions of the reusable product, sold as Vuse. FRIDAY, July 19, 2024 -- The U.S.

Marketing 105

Marketing FDA Production Drugs 105

Drug Patent Watch

JULY 24, 2024

As patents expire on blockbuster biologic drugs, manufacturers are increasingly employing a controversial tactic known as “product hopping” to maintain […] Source

Production 98

Production Marketing Drugs 98

Nvidia Developer: Drug Discovery

OCTOBER 30, 2024

The integration of AI in drug discovery is revolutionizing the way researchers approach the development of new treatments for various diseases. The integration of AI in drug discovery is revolutionizing the way researchers approach the development of new treatments for various diseases. Traditional.

Drugs 123

Drugs Treatment Disease Research 123

BioPharma Drive: Drug Pricing

JULY 22, 2024

Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.

Marketing 102

Marketing Drugs 102

Drug Target Review

JULY 4, 2023

Over the last two decades, an increasing number of Antibody Drug Conjugate (ADC) therapeutics have been approved for oncology indications. These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. 3D rendering of Antibody Drug Conjugate Molecules.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

Drug Channels

APRIL 9, 2024

Read on for Drug Channels Institute’s (DCI’s) latest market share figures, along with a preview of the industry changes that will shift these shares over the next few years. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. All rights reserved.

Pharmacy 92

Pharmacy Marketing Drugs 92

Drug Patent Watch

DECEMBER 12, 2024

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies.

Licensing 90

Licensing Licensing Drugs Biosimilars 90

BioPharma Drive: Drug Pricing

NOVEMBER 14, 2024

A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.

Regulations 124

Regulations Drugs Marketing 124

BioPharma Drive: Drug Pricing

NOVEMBER 11, 2024

Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a better bet in buying Karuna Therapeutics.

Drugs 131

Drugs Marketing 131

Drug Channels

MARCH 12, 2024

Next week, Drug Channels Institute (DCI) will release our 2024 Economic Report on U.S. drug pricing, reimbursement, and dispensing system. prescription dispensing revenues reached $621 billion in 2023, driven by accelerating GLP-1 prescriptions and an expanding post-pandemic market. Pharmacies and Pharmacy Benefit Managers.

Pharmacy 81

Pharmacy Marketing Drugs 81

Common Sense for Drug Policy Blog

NOVEMBER 15, 2024

Misrepresentation of Drugs in the Unregulated Market "The misrepresentation of illicit drugs is a persistent problem in unregulated markets ( Barratt et al., Results about drug content, including potentially dangerous substances, are then reported back to users and the community-at-large ( Barratt and Measham, 2022 ).

Marketing 52

Marketing Drugs 52

Drug Patent Watch

SEPTEMBER 19, 2024

The generic drug market in the United States is characterized by significant price volatility and shortages, driven by the structure of the market and the incentives for manufacturers. To address these issues, several market-based proposals have been put forth to optimize generic drug cost and availability.

Drugs 104

Drugs Marketing 104

Drug Patent Watch

SEPTEMBER 10, 2024

The generic drug market has experienced significant growth over the past few decades, driven by the passage of the Hatch-Waxman Act in 1984 and subsequent legislation. Today, the market is more competitive than ever, with generic drugs accounting for over 90% of all prescriptions in the United States.

Drug Development 105

Drug Development Drugs Marketing 105

Drug Channels

NOVEMBER 15, 2024

The authors outline the challenges that manufacturers face when integrating internal and external datasets to build market access and commercialization strategies. TThey argue that unified datasets and the addition of AI-driven analytics tools can improve decision making throughout a drug’s life cycle. Read on for their insights.

Marketing 80

Marketing International Drugs 80

BioPharma Drive: Drug Pricing

MAY 3, 2024

The company said data for its Wegovy competitor was promising enough to move the drug into late-stage testing, triggering a stock jump that added billions to Amgen’s market value.

Drugs 118

Drugs Marketing 118

Drug Channels

MARCH 28, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Bill discusses specialty therapy access barriers, including payer utilization management techniques and “no coverage” policies. Contact Mercalis to learn about their Patient Support Services. Read on for Bill’s insights. All rights reserved.

Marketing 81

Marketing Science Therapies Production 81

Drug Patent Watch

DECEMBER 5, 2024

In the ever-evolving landscape of healthcare, generic drugs play a crucial role in providing affordable and accessible medication to millions of people worldwide. But have you ever wondered about the journey these drugs take from conception to your local pharmacy shelf?

Marketing 90

Marketing Pharmacy Drugs Research 90

Drug Patent Watch

MAY 21, 2024

Annual Drug Patent Expirations for BELSOMRA Belsomra is a drug marketed by Merck Sharp Dohme and is included in one NDA. It is available from one supplier. There are two… Source

Drugs 105

Drugs Marketing 105

Drug Patent Watch

MAY 15, 2024

Annual Drug Patent Expirations for INOMAX Inomax is a drug marketed by Mallinckrodt Hosp and is included in one NDA. It is available from one supplier. There are fifteen patents… Source

Drugs 105

Drugs Marketing 105

Drug Patent Watch

MAY 22, 2024

Annual Drug Patent Expirations for NOCDURNA Nocdurna is a drug marketed by Ferring Pharms Inc and is included in one NDA. It is available from one supplier. There are four… Source

Drugs 105

Drugs Marketing 105

BioPharma Drive: Drug Pricing

JULY 16, 2024

The well-funded startup says drugs AbbVie abandoned last year could form a combination regimen with “superior efficacy” to Vertex’s market-leading medicines.

Drugs 116

Drugs Marketing 116

Drug Patent Watch

JUNE 27, 2024

Introduction Patent portfolios are critical assets for pharmaceutical companies, providing market exclusivity and protecting revenue streams for drug products. Effective management of drug patent portfolios requires strategic planning, ongoing evaluation, and adaptation to the evolving pharmaceutical landscape.

Pharmaceutical Companies 105

Pharmaceutical Companies Drugs Pharmaceuticals Production 105

Drug Patent Watch

MAY 30, 2024

Annual Drug Patent Expirations for KORLYM Korlym is a drug marketed by Corcept Therap and is included in one NDA. It is available from one supplier. There are sixteen patents… Source

Drugs 104

Drugs Marketing 104

Drug Patent Watch

MARCH 7, 2024

Annual Drug Patent Expirations for ULORIC Uloric is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are three… The post New patent expiration for Takeda Pharms drug ULORIC appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

Drugs 105

Drugs Marketing 105

Drug Patent Watch

FEBRUARY 17, 2024

Annual Drug Patent Expirations for AURYXIA Auryxia is a drug marketed by Keryx Biopharms and is included in one NDA. There are fourteen patents… The post New patent expiration for Keryx Biopharms drug AURYXIA appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

Drugs 105

Drugs Marketing 105

Drug Patent Watch

APRIL 21, 2024

Annual Drug Patent Expirations for SOOLANTRA Soolantra is a drug marketed by Galderma Labs Lp and is included in one NDA. It is available from three suppliers. There are twelve… Source

Drugs 105

Drugs Marketing 105

Drug Patent Watch

JUNE 19, 2024

In the ever-evolving pharmaceutical landscape, savvy businesses are constantly on the lookout for untapped markets and lucrative opportunities. One area that has garnered significant attention is the realm of low-competition generic drugs.

Drugs 110

Drugs Pharmaceuticals Marketing 110

Drug Patent Watch

OCTOBER 30, 2023

Annual Drug Patent Expirations for CALQUENCE Calquence is a drug marketed by Astrazeneca and is included in two NDAs. There are eight patents protecting… The post New patent for Astrazeneca drug CALQUENCE appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

Drugs 111

Drugs Marketing 111